DADC
NWBO

D.A. Davidson & Co’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

D.A. Davidson & Co’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4
Closed – – 2280
2014
Q3 		$0 Hold
4
– – ﹤0.01% 2277
2014
Q2 		$0 Hold
4
– – ﹤0.01% 2266
2014
Q1 		$0 Hold
4
– – ﹤0.01% 2309
2013
Q4 		$0 Hold
4
– – ﹤0.01% 2220
2013
Q3 		$0 Hold
4
– – ﹤0.01% 1882
2013
Q2 		$0 Buy
+4
New +$14 ﹤0.01% 1778

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.A. Davidson & Co's NWBO Position: Q4 2014 in Review

D.A. Davidson & Co sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2014, closing a stake of 4 shares.

D.A. Davidson & Co first reported a position in NWBO in Q2 2013 and held it in 6 quarters. The position peaked at $0 in Q3 2014. 70 funds tracked by Wall St. Rank hold NWBO as of Q4 2014.

  • D.A. Davidson & Co reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2014 after selling out during the quarter.
  • D.A. Davidson & Co sold 4 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2014.
  • D.A. Davidson & Co first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 6 quarters.
  • D.A. Davidson & Co's Northwest Biotherapeutics, Inc. Common stock position peaked at $0 in Q3 2014.
  • 70 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2014.

Based on D.A. Davidson & Co's 13F filing for Q4 2014, filed 12 Feb 2015.